NCT06917079View on ClinicalTrials.gov

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

287

Participants

Timeline

Start Date

March 31, 2025

Primary Completion Date

August 31, 2027

Study Completion Date

September 30, 2029

Conditions
Non-Small Cell Lung CancerNSCLCPDAC - Pancreatic Ductal AdenocarcinomaCRC (Colorectal Cancer)Metastatic Non-Small Lung Cell CancerMetastatic Colorectal Cancer (CRC)KRAS G12AKRAS G12CKRAS G12DKRAS G12SKRAS G12VMetastatic Pancreatic Ductal AdenocarcinomaAdvanced Lung CarcinomaSolid Tumor, Adult
Interventions
DRUG

BBO-11818

Participants will receive assigned dose of BBO-11818 orally (PO)

DRUG

Pembrolizumab

Patients will receive IV pembrolizumab

DRUG

Platinum chemotherapy (cisplatin or carboplatin)

Patients will receive IV platinum chemotherapy (cisplatin or carboplatin)

DRUG

Pemetrexed

Patients will receive IV pemetrexed

DRUG

Cetuximab

Patients will receive IV cetuximab

Trial Locations (8)

10032

RECRUITING

Columbia University Irving Medical Center, New York

33612

RECRUITING

Moffitt Cancer Center, Tampa

75230

RECRUITING

Sarah Cannon Research Institute at Mary Crowley, Dallas

77030

RECRUITING

The University of Texas MD Anderson Cancer Center, Houston

78229

RECRUITING

NEXT Oncology, San Antonio

84112

RECRUITING

Huntsman Cancer Institute, Salt Lake City

92037

RECRUITING

University of California San Diego Moores Cancer Center, San Diego

02114

RECRUITING

Massachusetts General Hospital, Boston

All Listed Sponsors
lead

TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

INDUSTRY